Search results for "Prognostic"

showing 10 items of 316 documents

Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome

2016

OBJECTIVE:The aim of this study was to evaluate over time circulating γδ T lymphocytes in melanoma patients in terms of frequency, effector functions, and relationship with clinical stage and evolution, by comparing preoperative values to those obtained at a mean follow-up of 36 months or in the event of recurrence or disease progression, and to those of healthy controls. Also, we correlated the presence of tumor-infiltrating γδ T lymphocytes with clinical evolution of melanoma. RESULTS:Mean frequencies of circulating γδ T cells before and after melanoma removal were very similar and comparable to healthy subjects, but patients who progressed to stage III or IV showed a significantly decrea…

MelanomasMale0301 basic medicineSkin NeoplasmsCellular differentiationmedicine.medical_treatmentSettore MED/19 - Chirurgia Plasticalcsh:MedicineWhite Blood Cells0302 clinical medicineAnimal CellsMedicine and Health SciencesMedicineCytotoxic T cellStage (cooking)lcsh:ScienceMelanomaγδ T lymphocytes melanoma prognostic biomarkerCultured Tumor CellsAged 80 and overMultidisciplinaryT CellsEffectorMelanomaCell DifferentiationReceptors Antigen T-Cell gamma-deltaMiddle AgedPrognosisPhenotypeSurgical OncologyPhenotypeCytokineOncology030220 oncology & carcinogenesisCutaneous MelanomaMelanoma CellsFemaleImmunotherapyBiological CulturesCellular TypesResearch ArticleAdultDeath RatesImmune CellsImmunologyMalignant Skin NeoplasmsSurgical and Invasive Medical ProceduresDermatologyResearch and Analysis Methods03 medical and health sciencesLymphocytes Tumor-InfiltratingPopulation MetricsHumansDemographyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleBlood CellsPopulation Biologybusiness.industrylcsh:RCase-control studyBiology and Life SciencesCancers and NeoplasmsCell BiologyCell Culturesmedicine.disease030104 developmental biologyCase-Control StudiesPeople and PlacesImmunologylcsh:QClinical ImmunologyClinical MedicinebusinessPLOS ONE
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical variables: development and validation of the PRIORITY …

2021

Objectives: We aimed to develop and validate a prediction model, based on clinical history and examination findings on initial diagnosis of coronavirus disease 2019 (COVID-19), to identify patients at risk of critical outcomes. Methods: We used data from the SEMI-COVID-19 Registry, a cohort of consecutive patients hospitalized for COVID-19 from 132 centres in Spain (23rd March to 21st May 2020). For the development cohort, tertiary referral hospitals were selected, while the validation cohort included smaller hospitals. The primary outcome was a composite of in-hospital death, mechanical ventilation, or admission to intensive care unit. Clinical signs and symptoms, demographics, and medical…

Microbiology (medical)medicine.medical_specialtyEvidence-based medicinePrognostic modelsReferralMedicinaCritical IllnessLogistic regressionInitial assessmentRisk Assessmentlaw.inventionlawmedicineHumansMedical historyGeneralizability theoryHospital MortalityRetrospective Studiesbusiness.industryMedicina basada en l'evidènciaCOVID-19Easily obtained clinical variablesGeneral MedicineModels Theoreticalmedicine.diseaseIntensive care unitConfidence intervalHospitalizationInfectious DiseasesSpainEmergency medicineCohortCritical illnessbusinessKidney disease
researchProduct

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

2020

BACKGROUND AND OBJECTIVE MYELOFIBROSIS: is an infrequent chronic myeloproliferative neoplasm. We aimed to describe the clinico-biological characteristics, treatment, and evolutive course of myelofibrosis patients in Spain.; MATERIAL AND METHODS: A total of 1,000 patients from the Spanish Registry of Myelofibrosis diagnosed with primary (n=641) or secondary (n=359) myelofibrosis were analysed.; RESULTS: Median age was 68 years. The frequency of constitutional symptoms, moderate to severe anaemia (Hb<10g/dL), and symptomatic splenomegaly was 35%, 36%, and 17%, respectively. The rate of thrombosis and haemorrhage was 1.96 and 1.6 events per 100 patient-years, respectively. The cumulative incid…

Moderate to severePediatricsmedicine.medical_specialtyConstitutional symptomsbusiness.industrymedicine.diseaseTransplantation03 medical and health sciences0302 clinical medicineChronic Myeloproliferative NeoplasmClinical heterogeneitymedicineElderly people030212 general & internal medicineMyelofibrosisbusinessPrognostic modelsMedicina Clínica (English Edition)
researchProduct

Prognostic value at 24 months of Multislice Computed Tomography Coronary Angiography in patients with atypical chest pain.

2009

Multislice Computed Tomography Coronary AngiographyAtypical chest painSettore MED/36 - Diagnostica Per Immagini E RadioterapiaPrognostic value
researchProduct

Prognostic outcome of atherosclerotic plaques in patients with suspected coronary artery disease assessed with Multislice Computed Tomography Coronar…

2010

Multislice Computed Tomography Coronary AngiographyPrognostic outcomeatherosclerotic plaqueSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Tri…

2021

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.

Neuroblastoma RAS viral oncogene homologOncologyCancer Researchgenetic riskMyeloid neoplasialeukemic cells0302 clinical medicinecytarabineclinical trials and observations:Other subheadings::/diagnosis [Other subheadings]MedicineComplete remissionazacytidineolder adultsRC254-282variantsLeukemiaAzacytidineHazard ratioleukemiaVariantsCytarabineacute:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [DISEASES]Neoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiaFludarabineLeukemiaOncology030220 oncology & carcinogenesisNGSOlder adultsLeucèmia mieloide aguda - Tractamentmyeloid neoplasiaMyelocyticmedicine.drugmedicine.medical_specialtymyelocyticcomplete remission:Otros calificadores::/diagnóstico [Otros calificadores]Subgroup analysisLeukemic cellsAcutePrognostic factorsArticle:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES]03 medical and health sciencesInternal medicineGenetic riskbusiness.industryprognostic factors:diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Odds ratio:Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]medicine.diseaseAvaluació de resultats (Assistència sanitària)CytarabinebusinessClinical trials and observations030215 immunology
researchProduct

Novelties in COPD prognosis: Evolution of survival indexes

2015

Despite several techniques, such as non-invasive ventilation (NIV), have improved the outcome of the acute exacerbation, COPD remains affected by poor prognosis in the medium and long term. Moreover, the task of predicting prognosis remains a major challenge for respiratory physicians. In order to overcome this limitation, several indexes have been proposed to assess the COPD patient in his/her complexity. The rationale is that, by using numerical indexes physicians may improve their clinical judgment to tailor and share therapeutical choices, i.e. referring the patient for surgery or lung transplantation. On this ground, Almagro et al. recently proposed the CODEX index, as the latest evolu…

Noninvasive VentilationSurvivalPrognosiPrognostic indexesSettore MED/10 - Malattie Dell'Apparato RespiratorioPrognosismortalitySurvival RatePulmonary Disease Chronic ObstructivePrognostic indexeLung transplantationCOPD; Extracorporeal carbon dioxide removal; Lung surgery; Lung transplantation; Non-invasive ventilation (NIV); Prognosis; Prognostic indexes; SurvivalExtracorporeal carbon dioxide removalHumansCOPDNon-invasive ventilation (NIV)Lung surgery
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities.

1999

In the present study, the expression of cyclin D1, as detected by immunohistochemistry, was compared with other prognostic variables and its prognostic impact was evaluated in a group of 172 patients with squamous cell carcinoma (SCC) of the esophagus who underwent potentially curative resection therapy and in a second group of 38 patients with SCC of the esophagus who were treated by combined modality therapy (radiochemotherapy ± surgery). Expression of cyclin D1 in surgically treated carcinomas correlated negatively with tumor differentiation (p = 0.026) but positively with mitotic activity (p = 0.0199) and nodal status (p = 0.040). There were no significant correlations with pT category.…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPrognostic variableEsophageal Neoplasmsmedicine.medical_treatmentLeucovorinCyclin D1EsophagusInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansCyclin D1EsophagusAgedEpirubicinAged 80 and overMucous MembraneEsophageal diseasebusiness.industryCancerEsophageal cancerMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurgeryRadiation therapySurvival Ratemedicine.anatomical_structureOncologyEpidermoid carcinomaCarcinoma Squamous CellFemaleFluorouracilCisplatinbusinessInternational journal of cancer
researchProduct